- Home
- » Tags
- » CDK inhibitor
Top View
- Targeting Transcription of MCL-1 Sensitizes HER2-Amplified Breast Cancers to HER2 Inhibitors
- Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells Fiona Simpkins1,2,3, Kibeom Jang1,4, Hyunho Yoon1, Karina E
- MEI Pharma Announces Study of Clinical Stage Oral CDK Inhibitor Voruciclib Published in Nature Scientific Reports
- Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
- Review Article CDK Inhibitors in Cancer Therapy, an Overview of Recent Development
- Combined CDK2 and CDK4/6 Inhibition Overcomes Palbociclib Resistance in Breast Cancer by Enhancing Senescence
- The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
- CDK9 Inhibitors in Acute Myeloid Leukemia Silvia Boffo1, Angela Damato1,2, Luigi Alfano3 and Antonio Giordano1,4*
- Targeting the Cyclin-Dependent Kinases (CDK) 4/6 in Estrogen Receptor-Positive Breast Cancers Richard S
- PDF Version of SABCS17 Highlights
- Cutting Edge Molecular Therapy for Acute Myeloid Leukemia
- CDK Inhibitors: Positive and Negative Regulators of G1-Phase Progression
- Targeted Therapies Forge Ahead in Multiple Breast Cancer Subtypes Jane De Lartigue, Phd
- Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
- Combination Strategies to Overcome Resistance to the BCL2 Inhibitor Venetoclax in Hematologic Malignancies Xiaoyan Yue†, Qingxiao Chen† and Jingsong He*
- Breast Systemic Treatment
- Targeting Multiple Signaling Pathways: the New Approach to Acute Myeloid Leukemia Therapy
- Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7 Shanhu Hu1, Jason J
- Prolonged Cetuximab Treatment Promotes P27kip1-Mediated G1 Arrest and Autophagy in Head and Neck Squamous Cell Carcinoma
- Cyclin-Dependent Kinase Inhibitors As Anticancer Therapeutics S
- Abemaciclib, a Selective€CDK4/6€Inhibitor Enhances the Radiosensitivity of Non-Small Cell Lung Cancer in Vitro and in Vivo
- Mechanisms of the CDK4/6 Inhibitor Palbociclib (PD 0332991) and Its Future Application in Cancer Treatment (Review)
- Rising to the Therapeutic Challenge of Head and Neck Cancer Jane De Lartigue, Phd
- The Discovery of a New Structural Class of Cyclin-Dependent Kinase Inhibitors, Aminoimidazo[1,2-A]Pyridines
- Myeloid Cell Leukemia-1 Dependence in Acute Myeloid Leukemia: a Novel Approach to Patient Therapy
- An Increased Cell Cycle Gene Network Determines MEK and Akt Inhibitor Double Resistance in Triple-Negative Breast Cancer
- MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1B Study in Patients with Indolent B- Cell Malignancies SAN DIEGO, Oct
- In Vitro Antitumor Properties of a Novel Cyclin-Dependent Kinase Inhibitor, P276-00
- Current and Emerging Therapies for Patients with Acute Myeloid Leukemia: a Focus on MCL-1 and the CDK9 Pathway Lindsey Lyle, MS, PA-C, and Naval Daver, MD
- In Vitro Antitumor Properties of a Novel Cyclin-Dependent Kinase Inhibitor, P276-00
- Translating Cancer Biology Into Medicines
- Novel Treatment Options for Acute Myelocytic Leukemia
- Emerging Data and Future Directions for CDK4/6 Inhibitor Treatment of Patients with Hormone Receptor Positive HER2-Non-Amplified Metastatic Breast Cancer
- ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer – ABC
- CDK Inhibitors: a Promising New Class of Targeted Therapies
- Development of CDK4/6 Inhibitors: a Five Years Update
- Cisplatin Exposure Causes C-Myc-Dependent Resistance to CDK4/6 Inhibition in HPV-Negative Head and Neck Squamous Cell Carcinoma Anthony M
- A Compound Combination Screening Approach with Potential to Identify New Treatment Options for Paediatric Acute Myeloid Leukaemia
- Selumetinib Suppresses Cell Proliferation, Migration and Trigger Apoptosis, G1 Arrest in Triple-Negative Breast Cancer Cells
- Cyclin-Dependent Kinase Inhibitors in Hematological Malignancies—Current Understanding, (Pre-)Clinical Application and Promising Approaches
- Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
- Susan G. Komen for the Cure Virtual Metastatic Breast Cancer Conference 2020 Metastatic Breast Cancer Research: Past, Present, and Future Daniel F
- Quantifying CDK Inhibitor Selectivity in Live Cells
- Targeting Cyclin-Dependent Kinases for the Treatment of Pulmonary Arterial Hypertension
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance Ping Chen1, Nathan V
- Flavopiridol and Trastuzumab Synergistically Inhibit Proliferation of Breast Cancer Cells
- CDK4/6 Inhibitor Treatments in Patients with Hormone Receptor